Introduction {#sec1-1}
============

We are informing the dermatosurgical society about newly introduced therapeutic approaches that are different from the standard guidelines for treatment of melanoma in the international society. With the new described approach, the patients are successfully treated within one surgical session and are not subjected to the recommendations of the European and American guidelines for treatment of cutaneous melanoma. This is made possible by the careful measurement of the tumour thickness (preoperatively), as a mandatory initial condition is that the clinical and dermatoscopic characteristics of the lesion speak explicitly in favour of cutaneous melanoma.

The case is indicative of the new approach that is being presented and could be one of the possible major innovations in the field of melanoma surgery today \[[@ref1]\] \[[@ref2]\] \[[@ref3]\].

Case Report {#sec1-2}
===========

We are reporting for a 72-years-old patient who was admitted to the Department of Dermatology, Venereology and Dermatologic Surgery at the Medical Institute of Ministry of Interior, (MVR-Sofia) because of a new lesion, which is localised in the head region -- right parietal region. The complaints are from around 2 years. Reason for the hospitalisation - increase in the lesion size and the pigmentation intensity over the last 2 months. During the clinical and dermatoscopic examination were established the typical features of a malignant melanocytic lesion, namely: heterogeneous lesion regarding the colour gamut: light brown to black in places, appearing dark grey; comparatively clearly demarcated from the healthy tissue; with areas of elevation (with central localization); with diameter of 3.3 cm to 2.7 cm; mostly plaque-like or rather endophytically growing; with irregular shape, uneven distribution of the pigment; with areas of regression.

The measured with a high frequency ultrasound (15 MHz) (in an external institution) tumor thickness was established that this is most probably a malignant melanocytic lesion with tumor thickness less than 1 mm (0.98 to 1 mm). The histologically established postoperative tumor thickness was 1 mm, with no ulcerations, no signs of angiolymphatic invasion, no increased number of mitoses.

Arterial hypertension as co-morbidity was noticed. Systemic medication of Amlodipine 5 mg (0/0/1), Moxonidine 0\\.2 mg (0/0/1), Irbesartan 0.3 g (300 mg) (1/0/0) was prescribed. There is no anamnestic evidence of allergies to food and medications. Mildly enlarged several lymph nodes above the right common carotid artery established via ultrasound, without definitive evidence of metastatic involvement. Performed was a surgical treatment with field of surgical security of 1 cm in all directions, the defect was initially closed with expandable flap, as intraoperatively (because of the inability to fully adapt the wound edges) a decision was made to perform additional progressive (advancement) flap, the skin flap was mobilized from the proximal part of the skin of the skull and translocated in distal direction ([Fig. 1a](#F1){ref-type="fig"}-[1d](#F1){ref-type="fig"}). The defect was closed in the form of the letter Y (Y-plastic). The postoperative course was without complications. In order to monitor the enlarged lymph nodes, ambulatory antibiotic therapy was planned with clarithromycin 500 mg for a period of 10 days and repeated ultrasound control.

![1a) Patient with cutaneous melanoma; 1b) Surgical margins with 1 cm surgical safety filed, preoperative conditions; 1c) Intraoperative status; 1d) Postoperative clinical status](OAMJMS-6-673-g001){#F1}

Discussion {#sec1-3}
==========

Until now it was recommended to remove any melanocytic lesion with a field of surgical security of 0.4 to 0.5 cm, and subsequently to perform re-excisions with or without parallel drainage lymph node (depending on the established postoperative tumor thickness) \[[@ref1]\]. Thanks to this new approach, some patients could avoid one (or the secondary re-excision) surgical intervention, which could be interpreted as a significant advantage or probably also survival benefit \[[@ref1]\] \[[@ref2]\] \[[@ref3]\].
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